If you know anyone sleeping more soundly thanks to a CPAP machine, thank Peter Farrell, SM ’67. He founded Resmed, the ...

Few observers think of CPAP machines as common fare where the med-tech patent wars are concerned, but Resmed Corp. recently came away with a win in litigation that resulted in the nullification of the ...

Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...

The AirCurve 11 is designed to tailor its therapy to a user’s normal breathing patterns. (ResMed) As Philips reaches a consent decree agreement with the FDA that will temporarily suspend its sales of ...

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.

The goal is to streamline setup and reduce the manual adjustments needed at the start of CPAP therapy, when people are still tinkering with the mask fit and other issues. (ResMed) Resmed believes its ...

I initiate coverage of ResMed with a Hold rating, citing dominant OSA positioning but near-term competitive headwinds. RMD’s recurring revenue model leverages device sales, consumables, and SaaS, with ...